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ABSTRACT
Objective: To evaluate the resistance to femoral fractures among 
rats treated with the immunosuppressant tacrolimus FK-506 and 
compare these to untreated rats and rats treated with placebo. 
Methods: Ninety male Wistar rats were used. The animals were 
nine weeks old and weighed between 220 g and 280 g. The im-
munosuppressive agent tacrolimus was used in this study at a 
dose of 2 mg/kg/day, administered orally. The suspension was 
administered using an insulin syringe, and the maintenance 
therapeutic dose was sufficient to maintain the immunosup-
pressive activity. The animals were randomly divided into three 
groups (n = 30): group 1, no substance administered; group 2, 
administration of the immunosuppressant tacrolimus FK-506; 
and group 3, administration of the vehicle alone. Treatment with 
FK-506 was administered for 28 days. Total leukocyte counts 
and differential counts (lymphocytes, monocytes, eosinophils 
and neutrophils) were evaluated in order to monitor the immu-
nosuppressive effect. Bone densitometry analysis by means of 
dual-energy x-ray absorptiometry (DXA) was also performed 
before and after administration of the drug. To evaluate the 
resistance to flexion, a support device was developed so that me-
chanical tests using an EMIC universal testing machine could 
be carried out. Results: The results from the flexion resistance 
tests showed statistical differences between groups 1 and 2 (p 
= 0.001) and between groups 2 and 3 (p = 0.001). No statisti-
cal difference was found between groups 1 and 3 (p = 0.995). 
Conclusions: The femurs of rats treated with the immunosup-
pressive agent had lower mechanical strength than did those of 
normal rats and those that received placebo.
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INTRODUCTION
Osteoporosis is a systemic disease characterized by 
diminution of the bone mass per unit volume, without 
any significant reduction in the ratio between the mi-
neral and organic phases, or any qualitative changes 
in the matrix(1). It is associated with changes to bone 
microarchitecture and results in increased fragility of 
the skeleton, with a heightened risk of occurrences of 
fractures caused by minimal trauma(1-3). Bone in situ-
ations of osteoporosis has normal biological behavior 
regarding osteoid mineralization. What occurs is dise-
quilibrium between reabsorption (osteoclastic activity) 
and formation (osteoblastic activity)(1).
Although the commonest idea is that osteoporo-
sis primarily affects postmenopausal women, other 
populations are also at high risk. One of these groups is 
formed by organ transplant recipients. The longer these 
patients survive, the longer their exposure will be to be 
risks of fractures(4). Over recent decades, transplantation 
has become an effective therapy for end-stage kidney, 
liver, heart and lung diseases. Brazil has accompanied 
this progression in the number of transplantations(5).
The survival following transplantation ranges from 
50% of lung recipients after five years to 74% of kid-
ney recipients from identical HLA live donors after 
10 years(5).
Calcineurin-phosphatase inhibitors (cyclosporin and 
tacrolimus) are partly responsible for the greater survival 
of transplanted patients and for reductions in glucocorti-
coid levels. However, like glucocorticoids, calcineurin-
phosphatase inhibitors also cause diminution of bone 
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mass, and the greatest bone loss occurs during the first 
six months following transplantation, at the time when 
the immunosuppressive therapy is most aggressive(6). 
Despite the current trend towards using lower total doses 
of immunosuppressants, many patients with transplants 
still develop fractures as a complication(5,6).
The incidence of fractures is lower following kidney 
transplantation (7% to 11% among non-diabetic kidney 
recipients) and higher among the recipients of other or-
gans: 17.2% to 42% after liver transplantation, 18% to 
50% after heart transplantation and 25% to 29% after 
lung transplantation(4).
However, the estimates regarding the prevalence or 
incidence of fractures following transplantation vary 
greatly. This perhaps reflects factors such as differences 
in patient selection, immunosuppressant regimens and 
criteria used for diagnosing vertebral fractures(5).
The aim of the present study was to evaluate the resis-
tance to fracturing of femurs in rats that were treated with 
the immunosuppressant tacrolimus FK-506, in compari-
son with untreated rats and rats treated with placebo.
METHODS
Animals used
Ninety nine-week-old male Wistar rats (Rattus nor-
vegicus) weighing 220 to 280 g were used. The rats were 
provided by Cecal (Fiocruz, RJ) and were kept in cages 
(three animals per cage), in an air-conditioned environ-
ment at a temperature of 19 to 22°C and humidity of 
40% to 50%, with light/dark cycles of 12 hours each. 
The animals were fed with granulated feed (Nuvilab-
CR1, Nuvital, Curitiba, Paraná, Brazil) and non-gassy 
water, in accordance with the guidance for animal rese-
arch of the Osvaldo Cruz Foundation (Fiocruz), RJ.
MEDICATION
The medication used in this study was the immuno-
suppressant tacrolimus (PROGRAF®, Astellas, Ireland), 
administered orally (intragastrically) at a dose of 2.0 
mg/kg/day (maintenance dose) in a volume of 2 ml/kg/
day, as a suspension in water and 5% dextrose capsu-
les (PROGRAF® 5 mg capsules, Astellas, Ireland) over 
a 28-day experimentation period. The suspension was 
administered with the aid of an insulin syringe (Plas-
tipak® 1 ml, Becton Indústria Cirúrgica Ltda., Brazil). 
The animals’ weight was measured at the time of each 
application and the dose was adjusted as required. The 
animals were divided randomly into three groups:
Group 1: no substance administered;
Group 2: administration of the immunosuppres-
sant tacrolimus FK-506 (PROGRAF® 5 mg, Astellas, 
Ireland); and
Group 3: administered vehicle only.
BLOOD TESTS
The total leukocyte counts and differential leuko-
cyte counts (lymphocytes, monocytes, eosinophils 
and neutrophils) were evaluated on day 0 and at the 
time when the animals were sacrificed (day 28), with 
the aim of monitoring the immunosuppressant ef-
fect of the medication. Blood samples were collected 
from a cut made at the tip of the rats’ tails. The leu-
kocyte counts were made using an optical microscope 
(Olympus BX40, Tokyo, Japan).
MECHANICAL TESTS
The mechanical tests were performed on a universal 
machine (Emic DL 10.00, São José dos Pinhais, Brazil). 
For this, two devices were constructed: one in the shape 
of a claw, which was attached to the top of the machine 
and served for pulling the femur; and another device at 
the bottom of the machine that served as the fixation 
base for the bone (Figure 1). The speed used was 0.5 
mm/s. The load value and the displacement were recor-
ded and the maximum force required for fracturing the 
bone (Fmax) was noted.
Figure 1 – A) Device used for performing the mechanical 
tests; B) Close-up of a femur undergoing traction during the 
mechanical test
1A 1B
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Figure 2 – A) Machine used for densitometry analysis (Prod-
igy, GE/Lunar, USA); B) Scanned image of femur from X-ray 
densitometry (DXA), showing area selected for bone density 
evaluation
2A 2B
DENSITOMETRIC ANALYSIS
The bone mineral content (BMC) was measured and 
divided by the area in order to obtain the bone mine-
ral density (BMD) of each animal’s femurs. A dual-
energy X-ray absorptiometry (DXA) machine was used 
(Prodigy, GE/Lunar, USA). The femur was placed in a 
receptacle containing rice, to simulate the soft tissue. 
The bone scanning and data analysis were performed 
using the Prodigy software, version 1.3 (Prodigy, GE/
Lunar, USA) for small animals. The resolution (size 
in pixels) was 0.3 x 0.6 mm, with a collimator of 0.84 
mm in diameter. The width of the scanned area was 
9.9 mm and the length was 11.8 mm. The scan dura-
tion per femur was 0.5 min. The femur was scanned 
and its total area was selected (Figure 2) for the bone 
density evaluation.
RESULTS
Lymphocyte count and total leukocyte count
The lymphocyte count at time 0 was 7.71 ± 0.7 cells/
mm3. After 28 days, these values had decreased to 4.54 
± 0.3 cells/mm3), and thus there was a statistical diffe-
rence between times 0 and 28. There was also a reduc-
tion in the leukocyte count, going from 10.24 ± 0.8 to 
6.75 ± 0.6 cells/mm3 (p < 0.05).
Resistance to flexion
The results relating to resistance to flexion and frac-
turing showed statistical differences between the group 
treated with immunosuppressant and the untreated and 
placebo groups (Table 1).
Table 1 – Means, standard deviations and statistical analysis on 
the groups evaluated
Groups Mean (SD) Statistics*
1 171.18 (± 26.07) A
2 117.46 (± 23.19) B
3 169.98 (± 27.11) A
SD = standard deviation
* = statistical analysis, in which the same letters represent lack of statistical difference (p > 0.05)
Bone densitometry
Bone densitometry showed values that differed be-
tween the group that received the medication (140.9 ± 
12.0 µg/cm2) and the two groups that did not receive it 
(152.2 ± 3.4 and 153.5 ± 1.2 µg/cm2, respectively for 
groups 1 and 3). This difference was e valuated statis-
tically as p < 0.05.
DISCUSSION
Tacrolimus is a macrolide antibiotic that was dis-
covered in a Japanese laboratory in 1984, and it has 
been shown to have an efficient immunosuppressant 
effect. This drug is produced through fermentation of 
the bacterium Streptomyces tsukubaensis and is ca-
pable of suppressing the humoral and cell-mediated 
immune responses, thus representing an alternative to 
cyclosporin-A(7).
The clinical use of tacrolimus is increasing, and 
it is now considered to be the baseline drug in more 
than 80% of liver transplantations and 30% of kid-
ney transplantations(8). It acts through T cell activation 
and calcineurin blockade(8). One of the adverse effects 
from its use is that it acts negatively on the skeleton, 
STATISTICAL METHODS
The data obtained from the fracture resistance tests, 
densitometry, lymphocyte counts and total leukocyte 
counts were analyzed statistically with the aid of the 
SPSS 13.0 software (SPSS Inc., Chicago, Illinois, USA). 
The values were subjected to analysis of variance (Ano-
va), in order to determine whether there were any sta-
tistical differences between the groups, followed by the 
Tukey test. The results were considered to be statisti-
cally significant when P < 0.05.
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thereby increasing bone reabsorption and leading to 
significant bone loss.
Reductions in mineral mass lead to the notion that the 
number of fractures in such individuals may increase. Ba-
sed on this premise, the present study had the aim of eva-
luating the resistance to flexion and fracturing of femurs 
in rates that had been treated with this medication.
For this, a dose of 2.0 mg/kg/day was used. This was 
the same as used by Sabry et al(9), who evaluated three 
different doses of tacrolimus in rats that had received 
transplants (3.2 mg/kg/day, 2.0 mg/kg/day and 1.0 mg/
kg/day, in the form of oral suspension). They observed 
that the dose of 2.0 mg/kg/day was sufficient to maintain 
the therapeutic serum levels without causing weight loss 
and with minimal side effects, thereby supporting the 
findings of Hayakawa et al(10). In the present study, we 
did not observe any weight loss among the rats treated 
with tacrolimus, or any clinically significant side effects 
such as pruritus(11), risk of infections(12) or diarrhea(12), 
which occur frequently in humans.
To monitor the immunosuppressant effect of the me-
dication, total and differential leukocyte counts were 
made during the experiment. After 28 days, there had 
been a decrease in the total leukocytes, which presented 
a statistically difference between the times 0 and 28 
days.
According to Cvetkovic et al(13), from the 14th day of 
tacrolimus use onwards, an imbalance in osteoblastic/
osteoclastic activity occurs. They stated that this could 
be associated with a significant increase in PTH levels 
(oral suspension of FK-506 at a dose of 3.2 mg/kg/day). 
This was confirmed by Kirino et al(14), who reported 
that there was a significant increase in the second week, 
with a maximum peak in the third week (intraperitoneal 
injection of FK-506 at a dose of 1.0 mg/kg/days), and 
that through continued administration of FK-506, the 
increase in PTH led to the start of bone tissue loss. To 
attempt to evaluate the loss of mineral mass, densito-
metric analysis was performed. The results showed that 
there was a statistical difference between the group that 
received tacrolimus and the other groups. This result 
corroborated the findings of Cvetkovic et al(13) and Ki-
rino et al(14).
Reports in the literature with contradictory results, 
and intense discussions regarding tacrolimus, have de-
monstrated that tacrolimus may induce bone loss in 
humans(6,15) and in experimental animal models(13,16,17).
The results relating to the decrease in mineral density 
presented between the animals in groups 1 and 3 and the 
animals in group 2 (tacrolimus group) were confirmed 
through the mechanical tests on the fracture resistance of 
these animals’ femurs. There was a significant decrease 
in the resistance to fracturing of the femurs from the 
treated rats (p < 0.05).
CONCLUSIONS
It can be concluded from this study that the femurs 
of the rats treated with the immunosuppressant tacroli-
mus FK-506 presented lower bone mineral density and 
lower resistance to flexion and fracturing than did the 
femurs of the rats treated with placebo and the femurs 
of the untreated rats.
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